These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32392256)

  • 1. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro.
    Kastl SP; Katsaros KM; Krychtiuk KA; Jägersberger G; Kaun C; Huber K; Wojta J; Speidl WS
    PLoS One; 2020; 15(5):e0232483. PubMed ID: 32392256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells.
    Lu L; Wang YN; Sun WH; Liu ZH; Zhang Q; Pu LJ; Yang K; Wang LJ; Zhu ZB; Meng H; Yang P; Du R; Chen QJ; Wang LS; Yu H; Shen WF
    Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):572-80. PubMed ID: 23372061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
    He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increment of HFABP Level in Coronary Artery In-Stent Restenosis Segments in Diabetic and Nondiabetic Minipigs: HFABP Overexpression Promotes Multiple Pathway-Related Inflammation, Growth and Migration in Human Vascular Smooth Muscle Cells.
    Chen K; Chen QJ; Wang LJ; Liu ZH; Zhang Q; Yang K; Wang HB; Yan XX; Zhu ZB; Du R; Zhang RY; Shen WF; Lu L
    J Vasc Res; 2016; 53(1-2):27-38. PubMed ID: 27372431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Euonymine inhibits in-stent restenosis through enhancing contractile phenotype of vascular smooth muscle cells via modulating the PTEN/AKT/mTOR signaling pathway.
    Zhang L; Tao Y; Yang R; Hu Q; Jia J; Yu M; He B; Shen Z; Qin H; Yu Z; Chen P
    Phytomedicine; 2022 Dec; 107():154450. PubMed ID: 36174454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
    Zamani M; Prabhakaran MP; Varshosaz J; Mhaisalkar PS; Ramakrishna S
    Acta Biomater; 2016 Sep; 42():316-328. PubMed ID: 27397493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secreted Matrix Metalloproteinase-9 of Proliferating Smooth Muscle Cells as a Trigger for Drug Release from Stent Surface Polymers in Coronary Arteries.
    Gliesche DG; Hussner J; Witzigmann D; Porta F; Glatter T; Schmidt A; Huwyler J; Meyer Zu Schwabedissen HE
    Mol Pharm; 2016 Jul; 13(7):2290-300. PubMed ID: 27241028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.
    Voisard R; Krebs R; Baur R; Hombach V
    Coron Artery Dis; 2010 Aug; 21(5):286-91. PubMed ID: 20508518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional evaluation of the spatial morphology of stented coronary artery segments in relation to restenosis.
    Üveges Á; Jenei C; Kiss T; Szegedi Z; Tar B; Szabó GT; Czuriga D; Kőszegi Z
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1755-1763. PubMed ID: 31127455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum TREM-1 level is associated with in-stent restenosis, and activation of TREM-1 promotes inflammation, proliferation and migration in vascular smooth muscle cells.
    Wang F; Li C; Ding FH; Shen Y; Gao J; Liu ZH; Chen JW; Zhang RY; Shen WF; Wang XQ; Lu L
    Atherosclerosis; 2017 Dec; 267():10-18. PubMed ID: 29080545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of plasma Quaking and cyclooxygenase-2 predict in-stent restenosis in patients with coronary artery disease after percutaneous coronary intervention.
    Wang P; Kuang Y; Liu Y; Zhang Y; Gao H; Ma Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):739-747. PubMed ID: 35837773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between fibrinogen-to-albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Chen T; Sun JL; Zhang J
    Coron Artery Dis; 2020 Nov; 31(7):586-589. PubMed ID: 32271235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.
    Hytönen J; Leppänen O; Braesen JH; Schunck WH; Mueller D; Jung F; Mrowietz C; Jastroch M; von Bergwelt-Baildon M; Kappert K; Heuser A; Drenckhahn JD; Pieske B; Thierfelder L; Ylä-Herttuala S; Blaschke F
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1534-48. PubMed ID: 27283742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.
    Cheng G; Chang FJ; Wang Y; You PH; Chen HC; Han WQ; Wang JW; Zhong NE; Min ZQ
    Med Sci Monit; 2019 Jan; 25():240-247. PubMed ID: 30617247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of M2BP in predicting in-stent restenosis in patients after coronary drug-eluting stent implantation.
    Yang L; Zhu H; Sun Y; Yan P; Song X; Xu F; Yuan H; Chen L
    Clin Cardiol; 2022 Mar; 45(3):308-314. PubMed ID: 35032135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.